Skip to main content

Table 1 Variation of glycans determined by lectin microarray analysis of SP cells and MP cells

From: Integrated glycomic analysis of ovarian cancer side population cells

No.

Lectin

Preferred glycan structure (terminal epitope)

SP1 ± SD

MP1 ± SD

SP1/MP1

SP2 ± SD

MP2 ± SD

SP2/MP2

1

LTL

Fuc α1-3(Gal β1-4)GlcNAc (Lex), Fuc α1-2(Gal β1-4)GlcNAc

0.40 ± 0.02

0.40 ± 0.02

1.00

0.42 ± 0.02

0.45 ± 0.02

0.95

2

PSA

Fuc α1-6GlcNAc, α-D-Glc, α-D-Man

0.78 ± 0.01

0.79 ± 0.06

0.99

0.82 ± 0.04

0.88 ± 0.02

0.93

3

LCA

Fuc α1-6GlcNAc, α-D-Glc, α-D-Man

0.91 ± 0.07

0.84 ± 0.06

1.08

0.89 ± 0.01

0.89 ± 0.03

0.99

4

UEA-I

Fuc α1-2(Gal β1-4)GlcNAc

0.41 ± 0.02

0.53 ± 0.03

0.78**

0.60 ± 0.02

0.61 ± 0.01

0.99

5

AOL

Fuc α1-6GlcNAc (core Fuc), Fuc α1-2(Gal β1-4)GlcNAc

0.93 ± 0.34

0.65 ± 0.04

1.43

0.58 ± 0.04

0.55 ± 0.04

1.05

6

AALª

Fuc α1-6GlcNAc (core Fuc), Fuc α1-3(Gal β1-4)GlcNAc (Lex)

1.22 ± 0.09

1.07 ± 0.04

1.14*

0.95 ± 0.05

0.87 ± 0.01

1.10*

7

MALª

Sia α2-3Gal β1-4GlcNAc

0.47 ± 0.02

0.60 ± 0.01

0.77***

0.63 ± 0.02

0.70 ± 0.01

0.90**

8

SNA

Sia α2-6Gal/GalNAc

0.82 ± 0.02

1.01 ± 0.05

0.81**

1.03 ± 0.03

0.90 ± 0.03

1.14**

9

SSA

Sia α2-6Gal/GalNAc

0.75 ± 0.04

0.90 ± 0.06

0.84*

1.03 ± 0.01

0.92 ± 0.01

1.11***

10

TJA-I

Sia α2-6Gal/GalNAc

1.65 ± 0.01

2.28 ± 0.08

0.73***

1.66 ± 0.15

1.56 ± 0.06

1.06

11

PHA-L

Tri/Tetra-antennary complex-type N-glycan

0.45 ± 0.03

0.45 ± 0.01

1.00

0.54 ± 0.01

0.59 ± 0.01

0.91**

12

ECA

Gal β1-4GlcNAc

0.86 ± 0.04

0.93 ± 0.04

0.93

1.12 ± 0.04

1.18 ± 0.04

0.95

13

RCA120

Gal β1-4GlcNAc

1.60 ± 0.07

2.43 ± 0.20

0.66**

2.13 ± 0.08

2.25 ± 0.12

0.95

14

PHA-E

Complex-type N-glycans with outer Gal and bisecting GlcNAc

0.75 ± 0.05

1.33 ± 0.06

0.57***

1.01 ± 0.02

0.88 ± 0.05

1.15*

15

DSAª

(GlcNAc β1-4)n, Gal β1-4GlcNAc, Tri/Tetra-antennary N-glycans

1.75 ± 0.03

2.21 ± 0.06

0.79***

1.78 ± 0.04

2.04 ± 0.04

0.87**

16

GSL-II

Agalactosylated tri/tetra antennary glycans, GlcNAc

0.48 ± 0.02

0.31 ± 0.00

1.52***

0.44 ± 0.02

0.43 ± 0.01

1.04

17

NPA

High Man, Man α1-6Man

1.52 ± 0.17

1.68 ± 0.03

0.90

1.41 ± 0.04

1.38 ± 0.07

1.02

18

ConA

High Man, Man α1-6(Man α1-3)Man (inhibited by presence of bisecting GlcNAc)

2.29 ± 0.23

2.23 ± 0.16

1.03

1.68 ± 0.11

1.59 ± 0.09

1.06

19

GNA

High Man, Man α1-3Man

0.98 ± 0.08

1.10 ± 0.01

0.89

1.02 ± 0.02

0.97 ± 0.03

1.05

20

HHL

High Man, Man α1-3Man, Man α1-6Man

0.67 ± 0.04

0.58 ± 0.01

1.17*

0.75 ± 0.02

0.74 ± 0.03

1.01

21

ACG

Sia α2-3Gal β1-4GlcNAc

1.36 ± 0.18

1.59 ± 0.09

0.85

1.38 ± 0.07

1.57 ± 0.05

0.88*

22

TxLC-I

Man3 core, bi- and tri-antennary complex-type N-glycan, GalNAc

1.06 ± 0.04

0.80 ± 0.05

1.32**

0.97 ± 0.05

0.93 ± 0.04

1.04

23

BPL

Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc

0.54 ± 0.05

0.53 ± 0.03

1.01

0.66 ± 0.02

0.63 ± 0.02

1.05

24

TJA-II

Fuc α1-2Gal β1-4, GalNAcβ1-4 groups at their nonreducing terminals

0.92 ± 0.04

1.01 ± 0.02

0.90*

1.11 ± 0.06

1.12 ± 0.03

0.99

25

EEL

Gal α1-3Gal β1-4GlcNAc, Fuc α1-2(Gal α1-3)Galβ1-4GlcNAc

0.58 ± 0.04

0.33 ± 0.02

1.74**

0.51 ± 0.02

0.52 ± 0.01

0.98

26

ABAª

Gal β1-3GalNAc (α-Thr/Ser (T)), GlcNAc, sialyl-T

2.16 ± 0.08

0.84 ± 0.06

2.58***

0.89 ± 0.01

0.84 ± 0.01

1.06*

27

LELª

(GlcNAc β1-4)n, (Gal β1-4GlcNAc)n (polyLacNAc)

2.39 ± 0.12

2.75 ± 0.16

0.87*

2.95 ± 0.08

3.16 ± 0.09

0.94*

28

STL

(GlcNAc)n, (GlcNAc β1-4MurNAc)n (peptidoglycan backbone)

1.77 ± 0.13

2.19 ± 0.14

0.81*

2.21 ± 0.16

2.36 ± 0.09

0.94

29

UDA

GlcNAc β1-4GlcNAc, Mixture of Man5 to Man9

1.65 ± 0.16

2.09 ± 0.32

0.79

1.62 ± 0.21

1.94 ± 0.26

0.84

30

PWM

(GlcNAc α1-4)n

0.52 ± 0.04

0.58 ± 0.08

0.90

0.82 ± 0.00

0.84 ± 0.03

0.98

31

Jacalin

Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn))

1.51 ± 0.25

1.55 ± 0.15

0.97

1.64 ± 0.04

1.60 ± 0.09

1.02

32

PNAª

Gal β1-3GalNAc (α-Thr/Ser (T))

0.68 ± 0.09

0.36 ± 0.01

1.86**

0.49 ± 0.01

0.43 ± 0.01

1.14**

33

WFA

Terminal GalNAc (e.g. GalNAcβ1-4GlcNAc), Galβ1-3(-6)GalNAc

0.52 ± 0.05

0.51 ± 0.02

1.03

0.71 ± 0.08

0.66 ± 0.06

1.08

34

ACA

Gal β1-3GalNAc (α-Thr/Ser (T))

2.20 ± 0.15

1.16 ± 0.14

1.90***

0.87 ± 0.07

0.97 ± 0.05

0.90

35

MPA

Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn))

0.81 ± 0.08

0.50 ± 0.02

1.61**

0.71 ± 0.04

0.66 ± 0.04

1.08

36

HPA

α-Linked terminal GalNAc

0.89 ± 0.04

0.43 ± 0.05

2.08***

0.45 ± 0.03

0.45 ± 0.02

1.01

37

VVAª

α-linked terminal GalNAc (α-Thr/Ser (Tn), GalNAc α1-3Gal

0.55 ± 0.03

0.44 ± 0.02

1.24**

0.59 ± 0.03

0.43 ± 0.00

1.35***

38

DBA

GalNAc α1-3GalNAc (Blood group A), GalNAc α1-3GalNAc

0.41 ± 0.04

0.34 ± 0.01

1.21*

0.46 ± 0.01

0.46 ± 0.01

1.00

39

SBA

α or β-linked terminal GalNAc, GalNAc α1-3Gal

0.56 ± 0.06

0.51 ± 0.05

1.10

0.78 ± 0.04

0.66 ± 0.02

1.18**

40

Calsepaª

High Man (Man2-6), N-glycans including bisecting GlcNAc

0.79 ± 0.05

0.66 ± 0.02

1.21*

0.80 ± 0.05

0.67 ± 0.02

1.20*

41

PTL-I

α-Linked terminal GalNAc

0.48 ± 0.03

0.53 ± 0.05

0.92

0.59 ± 0.04

0.50 ± 0.02

1.17*

42

MAH

Sia α2-3Gal β1-3(Sia α2-6) GalNAc

0.37 ± 0.03

0.49 ± 0.04

0.76*

0.53 ± 0.02

0.50 ± 0.02

1.05

43

WGAª

(GlcNAcβ1-4)n, NeuAc, multivalent Sia

1.32 ± 0.09

1.52 ± 0.07

0.87*

1.39 ± 0.02

1.48 ± 0.03

0.93**

44

GSL-IA4

α-GalNAc (α-Thr/Ser (Tn))

0.53 ± 0.06

0.43 ± 0.03

1.22

0.70 ± 0.01

0.63 ± 0.02

1.11**

45

GSL-IB4ª

α-Gal

0.75 ± 0.02

0.55 ± 0.03

1.35***

0.69 ± 0.01

0.62 ± 0.02

1.11**

  1. aSignificantly changed in two experiments; * p < 0.05; ** p < 0.01; *** p < 0.001